CompletedNCT00351936
Aripiprazole or placebo added to olanzapine for weight concerns in schizophrenia
About this title
Read the official source — NCT00351936Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- North Suffolk Mental Health Association
- Sponsor type
- Non-profit organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00351936
- Official title
Show the full official title
A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is North Suffolk Mental Health Association.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
